Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LT3001 in Acute Ischemic Stroke
NCT07890298Phase 2Recruiting
- Sponsor
- Lumosa Therapeutics
- Start
- Oct 2026
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of odatroltide in ischemic stroke, sponsored by Lumosa Therapeutics. Primary endpoint: Rate of successful recanalization at 24 hours. Started Oct 2026; status: recruiting.
02
Drugs
odatroltide
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT07890298.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07890298.